Shield TherapeuticsSTU:1JS -2.16% Gross Margin % is 44.07% as of Dec. 2025, which is 5% below its 10-year median of 46.38. The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Shield Therapeutics ranks worse than 53.62% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Shield Therapeutics had a gross margin of 44.07% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Shield Therapeutics Gross Margin % Related Terms
Shield Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1JS vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Shield Therapeutics (STU:1JS) has a Gross Margin % of 44.07% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Shield Therapeutics and its competitors. This is near median its historical median of 46.38. Over the past decade, Shield Therapeutics' Gross Margin % has ranged from 30.77 to 97.38. According to the industry distribution chart, Shield Therapeutics ranks #503 out of 938 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is Shield Therapeutics' Gross Margin % too high?
Shield Therapeutics' current Gross Margin % of 44.07% is near median its 10-year median of 46.38. Over the past 10 years, this metric has ranged from a low of 30.77 to a high of 97.38. The Drug Manufacturers industry median Gross Margin % is 48.44. Shield Therapeutics' value of 44.07% is 9% below this industry median. Based on the distribution chart, Shield Therapeutics ranks #503 out of 938 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Shield Therapeutics' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #503 out of 938 companies for Gross Margin %. This places Shield Therapeutics in the lower half of its industry. The industry median Gross Margin % is 48.44. Shield Therapeutics' value of 44.07% is 9% below this benchmark. Historically, Shield Therapeutics' own Gross Margin % has ranged from 30.77 to 97.38 over the past decade. While the company's 10-year median is 46.38 vs. the industry median of 48.44, Shield Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current Gross Margin % of 44.07% is 9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Gross Margin % is 44.07%, which is near median its own 10-year median of 46.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 24.4% below its estimated fair value. The current Gross Margin % is 44.07%, which is near median its 10-year median of 46.38 and 9% below the Drug Manufacturers industry median of 48.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Gross Margin % is 44.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 